Grey Peptides News https://greypeptides.com/news/ Regulatory action, clinical trial readouts, and peptide pipeline developments — by the Grey Peptides News Desk. Every post paraphrased from primary sources with attribution. en-us © 2026 Grey Peptides editors@greypeptides.com (Grey Peptides News Desk) editors@greypeptides.com (Grey Peptides Editorial) Tue, 12 May 2026 00:00:00 +0000 Tue, 12 May 2026 00:00:00 +0000 1440 https://greypeptides.com/assets/og-image.png Grey Peptides News https://greypeptides.com/news/ 1200 630 REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass https://greypeptides.com/news/cagrisema-redefine-1-body-composition-eco2026/ https://greypeptides.com/news/cagrisema-redefine-1-body-composition-eco2026/ Tue, 12 May 2026 12:00:00 +0000 News Wire Trial Data Grey Peptides News Desk New post-hoc DXA findings from Novo Nordisk's pivotal CagriSema trial, presented at the European Congress on Obesity 2026, examine the muscle-mass and lean-tissue picture behind 20%+ weight loss. The FDA Just Proposed Ending Mass GLP-1 Compounding — Here's What It Actually Means https://greypeptides.com/news/fda-503b-bulks-glp1-compounding-end/ https://greypeptides.com/news/fda-503b-bulks-glp1-compounding-end/ Fri, 01 May 2026 12:00:00 +0000 News Wire Regulation Grey Peptides News Desk On April 30, the FDA published a proposed rule that would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The compounding workaround is closing — but slower than the headlines suggest. PIONEER TEENS: Oral Semaglutide Posts Positive Phase 3 Results in Pediatric Type 2 Diabetes https://greypeptides.com/news/pioneer-teens-oral-semaglutide-pediatric/ https://greypeptides.com/news/pioneer-teens-oral-semaglutide-pediatric/ Fri, 24 Apr 2026 12:00:00 +0000 News Wire Trial Data Grey Peptides News Desk Novo Nordisk reported topline results from a phase 3a trial of oral semaglutide in patients aged 10 to 17 with type 2 diabetes — the first oral GLP-1 RA to clear a pivotal study in this group. FDA Pulls 12 Peptides Off Its "Do Not Compound" List — What Changes, and What Doesn't https://greypeptides.com/news/fda-12-peptides-category-2-removal/ https://greypeptides.com/news/fda-12-peptides-category-2-removal/ Wed, 22 Apr 2026 12:00:00 +0000 News Wire Regulation Grey Peptides News Desk On April 15, the FDA quietly removed twelve peptide bulk substances from Category 2 of the 503A interim policy. A July advisory-committee vote will decide whether they actually become compoundable. Wegovy HD Cleared in 54 Days: What the FDA's New Voucher Pathway Means for Peptide Drugs https://greypeptides.com/news/wegovy-hd-cnpv-approval-speed/ https://greypeptides.com/news/wegovy-hd-cnpv-approval-speed/ Wed, 15 Apr 2026 12:00:00 +0000 News Wire Regulation Grey Peptides News Desk The FDA approved semaglutide 7.2 mg on March 19 — fifty-four days after filing — using the Commissioner's National Priority Voucher pathway. Faster reviews are great. The precedent is more complicated. Foundayo (Orforglipron) Approved: The First Oral Small-Molecule GLP-1 for Weight Loss https://greypeptides.com/news/foundayo-orforglipron-fda-approval/ https://greypeptides.com/news/foundayo-orforglipron-fda-approval/ Thu, 02 Apr 2026 12:00:00 +0000 News Wire Approval Grey Peptides News Desk On April 1, the FDA approved Eli Lilly's orforglipron under the brand Foundayo. Unlike oral Wegovy, it's a small-molecule pill that doesn't require an empty stomach — and pricing is undercutting injectables.